Cargando…

Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2

The low proportion of gastric cancer (GC) patients with high HER2 expression limits the clinical application of trastuzumab, a humanized epidermal growth factor receptor 2 (HER2) antibody targeting for GC treatment. We found that Dicer was positively correlated with HER2 expression in GC tissue by i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jianhua, Zhao, Qun, Zhao, Yue, Zhang, Xiaoyun, Tian, Yuan, Guo, Zhanjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997953/ https://www.ncbi.nlm.nih.gov/pubmed/33772068 http://dx.doi.org/10.1038/s41598-021-86485-8

Ejemplares similares

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer
por: Mukai, Hirofumi, et al.
Publicado: (2016)

Nestin overexpression reduces the sensitivity of gastric cancer cells to trastuzumab
por: Wei, Yi-Chou, et al.
Publicado: (2023)

Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy
por: Kadowaki, Shigenori, et al.
Publicado: (2014)

Autophagy flux inhibition augments gastric cancer resistance to the anti-human epidermal growth factor receptor 2 antibody trastuzumab
por: Ye, Hua, et al.
Publicado: (2018)

Prognostic significance of Dicer expression in hepatocellular carcinoma
por: ZHANG, LI, et al.
Publicado: (2016)

Dicer Enhances Bevacizumab-Related Inhibition of Hepatocellular Carcinoma via Blocking the Vascular Endothelial Growth Factor Pathway
por: Wang, Cuiju, et al.
Publicado: (2021)

A study of human epidermal growth factor receptor 2 overexpression by immunohistochemistry in patients with gastric adenocarcinoma
por: ABOOD, RAFID A., et al.
Publicado: (2023)

Dicer Suppresses Hepatocellular Carcinoma via Interleukin-8 Pathway
por: Han, Xin, et al.
Publicado: (2023)

Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study
por: Piotrowski, Grzegorz, et al.
Publicado: (2012)

Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India
por: Joel, Anjana, et al.
Publicado: (2021)

Locoregional therapy with α‐emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2‐positive gastric cancer in mice
por: Li, Huizi Keiko, et al.
Publicado: (2017)

Overexpression of GSE1 Related to Trastuzumab Resistance in Gastric Cancer Cells
por: Wang, Wenbin, et al.
Publicado: (2021)

Correlation between the overexpression of epidermal growth factor receptor and pathological features of gastric cancer: a meta-analysis
por: Cui, Fan, et al.
Publicado: (2021)

Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2020)

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Kim, Hye Ryeon, et al.
Publicado: (2021)

p53 mutation and epidermal growth factor receptor overexpression in glioblastoma.
por: Yoon, K. S., et al.
Publicado: (2001)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2022)

Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer
por: Shimizu, Hiroko, et al.
Publicado: (2023)

Evaluation of Human Epidermal Growth Factor Receptor 2 Overexpression, Clinicopathological Characteristics, and Factors Affecting Survival in Gastric Cancer
por: Celayir, Ozde Melisa, et al.
Publicado: (2021)

Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2–overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study
por: Lavingia, Viraj, et al.
Publicado: (2022)

Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab
por: Ma, Pengkai, et al.
Publicado: (2015)

Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer
por: Gulia, Seema, et al.
Publicado: (2016)

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019)

Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
por: Yamaguchi, Kensei, et al.
Publicado: (2023)

Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric Cancer
por: Hino, Kaori, et al.
Publicado: (2022)

A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer
por: Arigami, Takaaki, et al.
Publicado: (2022)

Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
por: Haslem, Derrick S., et al.
Publicado: (2017)

The expression of epidermal growth factor receptor 1 and human epidermal growth factor receptor 2 based on tumor location affect survival in gastric cancer
por: Li, Guo-Cai, et al.
Publicado: (2020)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Quantifying the Effects of Combination Trastuzumab and Radiation Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Bloom, Meghan J., et al.
Publicado: (2022)

In Silico Study: Combination of α-Mangostin and Chitosan Conjugated with Trastuzumab against Human Epidermal Growth Factor Receptor 2
por: Megantara, Sandra, et al.
Publicado: (2022)

Identification of Genes Predicting Poor Response of Trastuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
por: Dong, Xinrui, et al.
Publicado: (2022)

Epidermal growth factor receptor structural alterations in gastric cancer
por: Moutinho, Cátia, et al.
Publicado: (2008)

Safety and Tolerability of Docetaxel, Cyclophosphamide, and Trastuzumab Compared to Standard Trastuzumab-Based Chemotherapy Regimens for Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Jitawatanarat, Potjana, et al.
Publicado: (2014)

Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis
por: Tian, Wei-Jie, et al.
Publicado: (2016)

Correlation between the overexpression of epidermal growth factor receptor and mesenchymal makers in endometrial carcinoma
por: Yang, Wei-Ning, et al.
Publicado: (2014)

Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer
por: YOSHIMOTO, Sho, et al.
Publicado: (2020)

Expression of transforming growth factor alpha, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma.
por: Filipe, M. I., et al.
Publicado: (1995)

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Al‐Batran, Salah‐Eddin, et al.
Publicado: (2020)

Risk Factors Associated with Trastuzumab-induced Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
por: Abdel-Razaq, Wesam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p1bh8mdp7rivbtnaqnmqcd07tq